News

Targeted Oncology10d
FDA to Review Nogapendekin Alfa in Bladder Cancer and Lymphopenia
A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...
Business Wire4d
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA ® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive ...
Pharmabiz8d
ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia
ImmunityBio, Inc, a leading immunotherapy company, announced that it has completed multiple submissions to the US FDA including an sBLA for BCG-unresponsive NMIBC in papillary disease and an EAP for ...
Yahoo Finance6mon
ImmunityBio, Inc. (IBRX)
April 21, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive ...